TY - JOUR
T1 - Effectiveness of Mindfulness-Based Cognitive Therapy with Follow-Up Sessions for Pharmacotherapy-Refractory Anxiety Disorders
T2 - Protocol for a Feasibility Randomized Controlled Trial
AU - Sado, Mitsuhiro
AU - Ninomiya, Akira
AU - Nagaoka, Maki
AU - Koreki, Akihiro
AU - Goto, Naho
AU - Sasaki, Yohei
AU - Takamori, Chie
AU - Kosugi, Teppei
AU - Yamada, Masashi
AU - Park, Sunre
AU - Sato, Yasunori
AU - Fujisawa, Daisuke
AU - Nakagawa, Atsuo
AU - Mimura, Masaru
N1 - Funding Information:
We would like to thank Editage for English language editing. We also thank Ms Tatsumi Kobayashi for arranging the schedule and assisting in the operation of the interventions. This study was funded by a grant from the Japan Agency for Medical Research and Development (grant number: 20lk0310059h0002). The funding source has no role in the study design, data collection, analysis, and interpretation; in the writing of the report; or in the decision to submit the paper for publication.
Publisher Copyright:
©Mitsuhiro Sado, Akira Ninomiya, Maki Nagaoka, Akihiro Koreki, Naho Goto, Yohei Sasaki, Chie Takamori, Teppei Kosugi, Masashi Yamada, Sunre Park, Yasunori Sato, Daisuke Fujisawa, Atsuo Nakagawa, Masaru Mimura.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Augmented mindfulness-based cognitive therapy (MBCT) with treatment as usual (mainly pharmacotherapy) is reported to be effective after treatment for anxiety disorders. However, whether its effectiveness persists in the long term is unclear. Objective: This study aims to examine the feasibility, acceptability, and effectiveness of a follow-up program by conducting a feasibility randomized controlled trial (RCT) that compares augmented MBCT with follow-up sessions and that without follow-up sessions in preparation for a definitive RCT. Methods: The study involves an 8-week MBCT with a 10-month follow-up. Patients aged 20 to 65 years who meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for panic disorder, agoraphobia, or social anxiety disorder, which is not remitted with usual treatment for at least 4 weeks, will be included in the study and randomly allocated to receive augmented MBCT with follow-up sessions or augmented MBCT without follow-up sessions. For this feasibility RCT, the primary outcomes are (1) study inclusion rate, (2) dropout rate, (3) attendance rate, and (4) mean and standard deviation of several clinical measures at 8 weeks and 5, 8, and 12 months. Results: We started recruiting participants in January 2020, and 43 participants have been enrolled up to January 2021. The study is ongoing, and data collection will be completed by May 2022. Conclusions: This study is novel in terms of its design, which compares augmented MBCT with and without follow-up sessions. The limitations of the trial are as follows: (1) mixed participants in terms of the delivery mode of the intervention, and (2) lack of a pharmacotherapy-alone arm. Owing to its novelty and significance, this study will provide fruitful knowledge for future definitive RCTs.
AB - Background: Augmented mindfulness-based cognitive therapy (MBCT) with treatment as usual (mainly pharmacotherapy) is reported to be effective after treatment for anxiety disorders. However, whether its effectiveness persists in the long term is unclear. Objective: This study aims to examine the feasibility, acceptability, and effectiveness of a follow-up program by conducting a feasibility randomized controlled trial (RCT) that compares augmented MBCT with follow-up sessions and that without follow-up sessions in preparation for a definitive RCT. Methods: The study involves an 8-week MBCT with a 10-month follow-up. Patients aged 20 to 65 years who meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for panic disorder, agoraphobia, or social anxiety disorder, which is not remitted with usual treatment for at least 4 weeks, will be included in the study and randomly allocated to receive augmented MBCT with follow-up sessions or augmented MBCT without follow-up sessions. For this feasibility RCT, the primary outcomes are (1) study inclusion rate, (2) dropout rate, (3) attendance rate, and (4) mean and standard deviation of several clinical measures at 8 weeks and 5, 8, and 12 months. Results: We started recruiting participants in January 2020, and 43 participants have been enrolled up to January 2021. The study is ongoing, and data collection will be completed by May 2022. Conclusions: This study is novel in terms of its design, which compares augmented MBCT with and without follow-up sessions. The limitations of the trial are as follows: (1) mixed participants in terms of the delivery mode of the intervention, and (2) lack of a pharmacotherapy-alone arm. Owing to its novelty and significance, this study will provide fruitful knowledge for future definitive RCTs.
KW - Anxiety disorders
KW - Cost-effectiveness
KW - Long-term effects
KW - Mindfulness-based cognitive therapy
KW - Randomized controlled trial
UR - http://www.scopus.com/inward/record.url?scp=85124124175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124124175&partnerID=8YFLogxK
U2 - 10.2196/33776
DO - 10.2196/33776
M3 - Article
AN - SCOPUS:85124124175
SN - 1929-0748
VL - 11
JO - JMIR Research Protocols
JF - JMIR Research Protocols
IS - 1
M1 - e33776
ER -